IL17A and metabolic syndrome: Over the last several decades, OA and the metabolic syndrome are increasingly recognized as the low-grade inflammatory condition with elevations in systemic inflammatory mediators such as Interleukin-1 (IL-1), Interleukin-6 (IL-6), and Tumor necrosis factor (TNF), and Interleukin-17 (IL-17)\*MERGEFORMAT [16].